Literature DB >> 12206843

Quality of life and sexuality of men with prostate cancer 3 years after cryosurgery.

John W Robinson1, Bryan J Donnelly, John C Saliken, Bryce A Weber, Scott Ernst, John C Rewcastle.   

Abstract

The current study was designed to describe the long-term life quality and sexuality of men enrolled in a phase 2 clinical trial of cryosurgery for the treatment of localized prostate cancer. A total of 75 men were administered the Functional Assessment of Cancer Treatment-Prostate (FACT-P) before treatment and after treatment at 6 weeks, and at 3, 6, 12, 24, and 36 months. Additionally, these men completed a Sexuality Follow-Up Questionnaire (SFQ) 3 years after cryosurgery. By 12 months after cryosurgery, most FACT-P subscales had returned to pretreatment levels. Quality of life remained stable over the subsequent 2 years. The only exception to this general trend was persistent impairment in measures of social/family well-being. At 36 months, 13% (5 of 38) of patients had regained erectile functioning, and an additional 34% (13 of 38) of patients were sexually active with the help of aids. The 3-year quality-of-life outcomes support the renewed interest in cryosurgery. No late complications were observed. Whereas improvements in erectile function were observed between years 1 and 3 for some patients, most continue to experience erectile dysfunction. For these patients, aids are an important adjunct to the treatment of their erectile dysfunction.

Entities:  

Mesh:

Year:  2002        PMID: 12206843     DOI: 10.1016/s0090-4295(02)01679-5

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

Review 1.  Cryotherapy.

Authors:  Katsuto Shinohara
Journal:  Int J Clin Oncol       Date:  2007-12-21       Impact factor: 3.402

2.  Effects of Focal vs Total Cryotherapy and Minimum Tumor Temperature on Patient-reported Quality of Life Compared With Active Surveillance in Patients With Prostate Cancer.

Authors:  Glenn T Werneburg; Michael Kongnyuy; Daniel M Halpern; Jose M Salcedo; Connie Chen; Amanda LeSueur; Kaitlin E Kosinski; Jeffrey T Schiff; Anthony T Corcoran; Aaron E Katz
Journal:  Urology       Date:  2017-12-23       Impact factor: 2.649

3.  Cancer-specific concerns and physical activity among recently diagnosed breast and prostate cancer survivors.

Authors:  Allison Ottenbacher; Richard Sloane; Denise C Snyder; William Kraus; Lisa Sprod; Wendy Demark-Wahnefried
Journal:  Integr Cancer Ther       Date:  2012-08-09       Impact factor: 3.279

Review 4.  The current and potential role of cryoablation as a primary therapy for localized prostate cancer.

Authors:  Aaron E Katz; John C Rewcastle
Journal:  Curr Oncol Rep       Date:  2003-05       Impact factor: 5.075

5.  New techniques and management options for localized prostate cancer.

Authors:  Joycelyn L Speight; Mack Roach
Journal:  Rev Urol       Date:  2006

6.  Comparison of health-related quality of life and prostate-associated symptoms after primary and salvage cryotherapy for prostate cancer.

Authors:  Aristotelis G Anastasiadis; Reena Sachdev; Laurent Salomon; Mohamed A Ghafar; Brian C Stisser; Ridwan Shabsigh; Aaron E Katz
Journal:  J Cancer Res Clin Oncol       Date:  2003-10-21       Impact factor: 4.553

Review 7.  Critical review of the efficacy and safety of cryotherapy of the prostate.

Authors:  James Cliftton Vestal
Journal:  Curr Urol Rep       Date:  2005-05       Impact factor: 2.862

Review 8.  Primary cryotherapy for localised or locally advanced prostate cancer.

Authors:  Jae Hung Jung; Michael C Risk; Robert Goldfarb; Balaji Reddy; Bernadette Coles; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2018-05-30

9.  Value of T1/T2-weighted magnetic resonance imaging registration to reduce the postbiopsy hemorrhage effect for prostate cancer localization.

Authors:  Ja Yeon You; Hak Jong Lee; Sung Il Hwang; Yun Jung Bae; Hannah Kim; Helen Hong; Gheeyoung Choe
Journal:  Prostate Int       Date:  2015-07-17

10.  Patient-reported quality of life progression in men with prostate cancer following primary cryotherapy, cyberknife, or active holistic surveillance.

Authors:  Glenn T Werneburg; Michael Kongnyuy; Daniel M Halpern; Jose M Salcedo; Kaitlin E Kosinski; Jonathan A Haas; Jeffrey T Schiff; Anthony T Corcoran; Aaron E Katz
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-12-07       Impact factor: 5.554

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.